Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study
To explore the experience of non-small-cell lung cancer patients with targeted therapy-related skin adverse drug reactions. This is a descriptive quantitative study conducted in a comprehensive hospital in Henan, China. Purposive sampling was used to recruit patients with non-small-cell lung cancer...
Gespeichert in:
Veröffentlicht in: | Asia-Pacific Journal of Oncology Nursing 2022-10, Vol.9 (10), p.100115, Article 100115 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To explore the experience of non-small-cell lung cancer patients with targeted therapy-related skin adverse drug reactions.
This is a descriptive quantitative study conducted in a comprehensive hospital in Henan, China. Purposive sampling was used to recruit patients with non-small-cell lung cancer and with targeted therapy-related skin adverse drug reactions. In total, 23 patients were approached when the data were saturated. Face-to-face interviews were conducted by an independent researcher using a semi-structured interview guide. Interview data were transcribed and analyzed by qualitative inductive content analysis.
Based on the analysis, four main categories were identified according to patients’ descriptions of their experience: a lack of self-management ability, psychological and emotional problems, a barrier to social participation, and a need for social support. Suffering from persistent symptoms, insufficient knowledge, skills and strategies for skin adverse drug reaction management, psychological problems, social avoidance/withdrawal, and reduced willingness to work were core experiences that would affect patients' compliance with treatment, prognosis, and the overall quality of life.
This study revealed the real experience of patients with non-small-cell lung cancer and with targeted therapy-related skin adverse drug reactions which contributed to the development of targeted interventions to manage skin adverse reactions. |
---|---|
ISSN: | 2347-5625 2349-6673 |
DOI: | 10.1016/j.apjon.2022.100115 |